ArticleMucosal immunology2016
Nucleotide-binding oligomerization domain 1 acts in concert with the cholecystokinin receptor agonist, cerulein, to induce IL-33-dependent chronic pancreatitis.
Article in Mucosal immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 65 citations in OpenAlex.
- MZB1 Modulates Inflammatory Severity in Severe Acute Pancreatitis through an IgA-Associated Intestinal Barrier Axis.Inflammation · 2026Article
- IL-18 promotes pancreatic fibrosis via release of IL-4 from pancreatic stellate cells and induces macrophage M2 polarization.Scientific reports · 2026Article
- Cytomegalovirus-induced intrahepatic cholestasis complicated by hemophagocytic syndrome in an immunocompetent adult.Clinical journal of gastroenterology · 2026Article
- Article
- Gut Microbiota Involved in the Immunopathogenesis of Autoimmune Pancreatitis.Gut and liver · 2025Review
- WNT2B high‑expressed fibroblasts induce the fibrosis of IBD by promoting NK cells secreting IL-33.Journal of molecular medicine (Berlin, Germany) · 2024Article
- A positive cytokine/chemokine feedback loop establishes plasmacytoid DC-driven autoimmune pancreatitis in IgG4-related disease.JCI insight · 2024Article
- Circulating Markers of Necroptosis in Acute Pancreatitis.Digestive diseases and sciences · 2024Article
- High-mobility group box 1 fragment ameliorates chronic pancreatitis induced by caerulein in mice.Journal of gastroenterology · 2024Article
- High-mobility group box 1: friend or foe in pancreatitis.Journal of gastroenterology · 2024Article
- Reciprocal regulation of protein arginine deiminase 2 and 4 expression in the colonic mucosa of ulcerative colitis.Journal of clinical biochemistry and nutrition · 2024Article
- Functional role of IL-19 in a mouse model of L-arginine-induced pancreatitis and related lung injury.Experimental animals · 2024Article
- Cytokine and chemokine profiles in ulcerative colitis relapse after coronavirus disease 2019 vaccination.Journal of clinical biochemistry and nutrition · 2024Article
- Crosstalk between NOD2 and TLR2 suppresses the development of TLR2-mediated experimental colitis.Journal of clinical biochemistry and nutrition · 2024Article
- Role of leucine-rich repeat kinase 2 in severe acute pancreatitis.Frontiers in immunology · 2024Review
- Leucine-rich repeat kinase 2 promotes the development of experimental severe acute pancreatitis.Clinical and experimental immunology · 2023Article
- Regulation of type I IFN responses by deubiquitinating enzyme A in inflammatory bowel diseases.Journal of clinical biochemistry and nutrition · 2023Article
- Ulcerative Colitis-associated Spondyloarthritis Successfully Treated with Infliximab in the Absence of Enhanced TNF-α Responses.Internal medicine (Tokyo, Japan) · 2023Article
- Activation of the aryl hydrocarbon receptor inhibits the development of experimental autoimmune pancreatitis through IL-22-mediated signaling pathways.Clinical and experimental immunology · 2023Article
- Gut microbiota interacts with inflammatory responses in acute pancreatitis.Therapeutic advances in gastroenterology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Nucleotide-binding oligomerization domain 1 (NOD1) fulfills important host-defense functions via its responses to a variety of gut pathogens. Recently, however, we showed that in acute pancreatitis caused by administration of cholecystokinin receptor (CCKR) agonist (cerulein) NOD1 also has a role in inflammation via its responses to gut commensal organisms. In the present study, we explored the long-term outcome of such NOD1 responsiveness in a new model of chronic pancreatitis induced by repeated administration of low doses of cerulein in combination with NOD1 ligand. We found that the development of chronic pancreatitis in this model requires intact NOD1 and type I IFN signaling and that such signaling mediates a macrophage-mediated inflammatory response that supports interleukin (IL)-33 production by acinar cells. The IL-33, in turn, has a necessary role in the induction of IL-13 and TGF-β1, factors causing the fibrotic reaction characteristic of chronic pancreatitis. Interestingly, the Th2 effects of IL-33 were attenuated by the concomitant type I IFN response since the inflammation was marked by clear increases in IFN-γ and TNF-α production but only marginal increases in IL-4 production. These studies establish chronic pancreatitis as an IL-33-dependent inflammation resulting from synergistic interactions between the NOD1 and CCKR signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.